About Gennova
Gennova is a company based in Pune (India) founded in 2006. The company has 705 employees as of April 07, 2024. Gennova offers products and services including Elaxim®, GEMCOVAC®-OM, Hamsyl®, TENECTASE®, and Xgrast®. Gennova operates in a competitive market with competitors including Senti Biosciences, Calliditas Therapeutics, Ardelyx, Tenaya Therapeutics and Adicet Bio, among others.
- Headquarter Pune, India
- Employees 705 as on 07 Apr, 2024
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Gennova Biopharmaceuticals Limited
- Date of Incorporation 19 Jun, 2001
- Jurisdiction Pune City, Maharashtra, India
-
Annual Revenue
$45.26 M (USD)9.75as on Mar 31, 2023
-
Net Profit
$3.69 M (USD)83.26as on Mar 31, 2023
-
EBITDA
$11.5 M (USD)42.2as on Mar 31, 2023
-
Latest Funding Round
-
Investors
European Union
& 1 more
-
Employee Count
705
as on Apr 07, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gennova
Gennova offers a comprehensive portfolio of products and services, including Elaxim®, GEMCOVAC®-OM, Hamsyl®, TENECTASE®, and Xgrast®.
Biotherapeutic for cardiac care and acute myocardial infarction treatment.
mRNA-based vaccine targeting emerging diseases and health threats.
Treatment for renal care and anemia-related complications in patients.
Clot buster for stroke care to minimize treatment time and disabilities.
Solution for cancer care to address neutropenia and enhance treatments.
Funding Insights of Gennova
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Seed - Gennova | Valuation |
investors |
|
| Apr, 2020 | Amount | Grant - Gennova | Valuation |
investors |
Investors in Gennova
Gennova has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Department of Biotechnology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Biotechnology research, guidelines, and funding by the Government of India.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Gennova
Financial Statements - Gennova
Gennova Comparisons
Competitors of Gennova
Gennova operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Calliditas Therapeutics, Ardelyx, Tenaya Therapeutics and Adicet Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Immune cell therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Microbial therapeutics for skin diseases are developed.
|
Frequently Asked Questions about Gennova
Gennova was founded in 2006 and raised its 1st funding round 14 years after it was founded.
Gennova is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Sanjay Singh is the current CEO of Gennova.
As of Apr 07, 2024, the latest employee count at Gennova is 705.
Annual revenue of Gennova is $45.26M as on Mar 31, 2023.
Founded in 2006 in Pune, India, biotherapeutics targeting cardiovascular, neurology, nephrology, and oncology indications are developed and commercialized. Recombinant products are manufactured using bacterial, yeast, and mammalian expression platforms, with expertise applied in perfusion-based continuous manufacturing. Biosimilars, vaccines, generics, and innovative products have been commercialized, including an mRNA-based platform for vaccine development.
Gennova's top competitors include Senti Biosciences, Ardelyx and Tenaya Therapeutics.
Gennova offers Elaxim®, GEMCOVAC®-OM, Hamsyl®, TENECTASE®, and Xgrast®.
Gennova has 2 investors. Key investors include European Union, and Department of Biotechnology.